Vascular Biogenics Stock Beta
| VBLTDelisted Stock | USD 0.28 0.01 3.45% |
Vascular Biogenics fundamentals help investors to digest information that contributes to Vascular Biogenics' financial success or failures. It also enables traders to predict the movement of Vascular Stock. The fundamental analysis module provides a way to measure Vascular Biogenics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vascular Biogenics stock.
Vascular |
Vascular Biogenics Company Beta Analysis
Vascular Biogenics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Vascular Biogenics Beta | 0.71 |
Most of Vascular Biogenics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vascular Biogenics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Vascular Biogenics has a Beta of 0.7128. This is 17.12% lower than that of the Biotechnology sector and 48.72% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Vascular Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vascular Biogenics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vascular Biogenics could also be used in its relative valuation, which is a method of valuing Vascular Biogenics by comparing valuation metrics of similar companies.Vascular Biogenics is currently under evaluation in beta category among its peers.
As returns on the market increase, Vascular Biogenics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Vascular Biogenics is expected to be smaller as well.
Vascular Fundamentals
| Return On Equity | -0.6 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (33.89) % | |||
| Current Valuation | (10.99 M) | |||
| Shares Outstanding | 77.64 M | |||
| Shares Owned By Insiders | 13.48 % | |||
| Shares Owned By Institutions | 14.00 % | |||
| Number Of Shares Shorted | 250.34 K | |||
| Price To Earning | (9.32) X | |||
| Price To Book | 0.35 X | |||
| Price To Sales | 9.63 X | |||
| Revenue | 658 K | |||
| Gross Profit | 554 K | |||
| EBITDA | (31.16 M) | |||
| Net Income | (32.3 M) | |||
| Cash And Equivalents | 34.15 M | |||
| Cash Per Share | 0.49 X | |||
| Total Debt | 564 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 4.05 X | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (31.59 M) | |||
| Short Ratio | 0.55 X | |||
| Earnings Per Share | (0.18) X | |||
| Target Price | 5.0 | |||
| Beta | 0.71 | |||
| Market Capitalization | 13.83 M | |||
| Total Asset | 29.66 M | |||
| Retained Earnings | (294.38 M) | |||
| Working Capital | 15.42 M | |||
| Current Asset | 38.59 M | |||
| Current Liabilities | 4.16 M | |||
| Z Score | -2.01 | |||
| Net Asset | 29.66 M |
About Vascular Biogenics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vascular Biogenics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vascular Biogenics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vascular Biogenics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Transaction History View history of all your transactions and understand their impact on performance |